Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18548563 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL1232002 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL3185849 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL996469 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL3181704 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL6578082 | 0.92 | MEN1 (0.44) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL4140372 | 0.87 | USP2 (0.63) | TSHRALDH1A1USP2KDM4ELMNA | |
| SCHEMBL4154180 | 0.87 | USP2 (0.63) | TSHRALDH1A1USP2KDM4ELMNA | |
| SCHEMBL4149480 | 0.87 | USP2 (0.63) | TSHRALDH1A1USP2KDM4ELMNA | |
| SCHEMBL4148516 | 0.87 | USP2 (0.63) | TSHRALDH1A1USP2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008094203-A2 | POLAR ESTER PRODRUGS OF HETEROCYCLIC HYBRID ANTIBACTERIAL COMPOUNDS AND SALTS THEREOF | MICROBIOTIX, INC. (US) | 2008-08-07 | — | — | WO | claimed |
| CN-107935943-B | Ester-water amphiphilic hypocrellin derivative and preparation method and application thereof | 中国科学院理化技术研究所 | 2021-06-29 | — | — | CN | disclosed |
| US-10844076-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | NEKTAR THERAPEUTICS (US) | 2020-11-24 | — | — | US | disclosed |
| US-10808050-B2 | Antibody-drug conjugate having cyclic benzylidene acetal linker | NOF CORPORATION (JP) | 2020-10-20 | — | — | US | disclosed |
| CN-106604891-B | Non-aqueous liquid and semi-solid formulations of amorphous calcium carbonate | 艾玛菲克有限公司 | 2020-07-28 | — | — | CN | disclosed |
| US-20190309102-A1 | ANTIBODY-DRUG CONJUGATE HAVING CYCLIC BENZYLIDENE ACETAL LINKER | NOF CORPORATION (JP) | 2019-10-10 | — | — | US | disclosed |
| US-10377837-B2 | Antibody-drug conjugate having cyclic benzylidene acetal linker | NOF CORPORATION (JP) | 2019-08-13 | — | — | US | disclosed |
| US-20190071454-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-10189859-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | NEKTAR THERAPEUTICS (US) | 2019-01-29 | — | — | US | disclosed |
| EP-2842940-B1 | SULFORAPHANE-DERIVED COMPOUNDS, PRODUCTION METHOD THEREOF AND THE MEDICAL, FOOD AND COSMETIC USE OF SAME | CONSEJO SUPERIOR INVESTIGACION (ES) | 2018-04-25 | — | — | EP | disclosed |
| EP-2499113-A1 | HOMOGLUTAMIC ACID DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2012-09-19 | — | — | EP | disclosed |
| US-8133695-B2 | Fluorescence polarization hERG assay | Life Technologies Corporation (US) | 2012-03-13 | — | — | US | disclosed |
| WO-2011057986-A1 | HOMOGLUTAMIC ACID DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-19 | — | — | WO | disclosed |
| EP-2322514-A1 | Homoglutamic acid and glutamic acid derivatives | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-05-18 | — | — | EP | disclosed |
| EP-1856073-B1 | A PROCESS FOR THE PREPARATION OF AN 11-(4-SUBSTITUTED-I-PIPERAZINYL)DIBENZO[b,f][1,4]THIAZEPINE DERIVATIVE | UNION QUIMICO FARMA (ES) | 2010-05-12 | — | — | EP | disclosed |
| US-7655768-B2 | Galactose derivative, drug carrier and medicinal composition | NIPPON SHINYAKU CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-20090253148-A1 | FLUORESCENCE POLARIZATION hERG ASSAY | Life Technologies Corporation (US) | 2009-10-08 | — | — | US | disclosed |
| WO-2008094203-A2 | POLAR ESTER PRODRUGS OF HETEROCYCLIC HYBRID ANTIBACTERIAL COMPOUNDS AND SALTS THEREOF | MICROBIOTIX, INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20070244058-A1 | Galactose Derivative, Drug Carrier and Medicinal Composition | NIPPON SHINYAKU CO., LTD. (JP) | 2007-10-18 | — | — | US | disclosed |
| US-7230101-B1 | Synthesis of methotrexate-containing heterodimeric molecules | GPC BIOTECH, INC. (US) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377837-B2 | Antibody-drug conjugate having cyclic benzylidene acetal linker | H1-2, CD22, H1-0 | MEN1 289/4885KMT2A 303/4885TSHR 96/4885 |
| US-10844076-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | KCNJ2, TRPC5, RYR2 | MEN1 1531/4885KMT2A 464/4885TSHR 508/4885 |
| US-10808050-B2 | Antibody-drug conjugate having cyclic benzylidene acetal linker | H1-2, CD22, H1-0 | MEN1 289/4885KMT2A 303/4885TSHR 96/4885 |
| US-20190309102-A1 | ANTIBODY-DRUG CONJUGATE HAVING CYCLIC BENZYLIDENE ACETAL LINKER | H1-2, CD22, H1-0 | MEN1 289/4885KMT2A 303/4885TSHR 96/4885 |
| US-20190071454-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | KCNJ2, TRPC5, RYR2 | MEN1 1531/4885KMT2A 464/4885TSHR 508/4885 |
| US-20070244058-A1 | Galactose Derivative, Drug Carrier and Medicinal Composition | GALK1, GALE, UGGT1 | MEN1 4716/4885KMT2A 2876/4885TSHR 2018/4885 |
| US-10189859-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | KCNJ2, TRPC5, RYR2 | MEN1 1531/4885KMT2A 464/4885TSHR 508/4885 |
| US-20090253148-A1 | FLUORESCENCE POLARIZATION hERG ASSAY | TNNI3, TNNT2, KCNQ1 | MEN1 3369/4885KMT2A 3201/4885TSHR 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.